KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Current Investments (2016 - 2026)

Biomarin Pharmaceutical's Cash & Current Investments history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 37.17% year-over-year to $1.6 billion, compared with a TTM value of $1.6 billion through Dec 2025, up 37.17%, and an annual FY2025 reading of $1.6 billion, up 37.17% over the prior year.
  • Cash & Current Investments for Q4 2025 was $1.6 billion at Biomarin Pharmaceutical, up from $1.5 billion in the prior quarter.
  • The five-year high for Cash & Current Investments was $1.6 billion in Q4 2025, with the low at $930.4 million in Q3 2024.
  • Average Cash & Current Investments over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
  • Year-over-year, Cash & Current Investments dropped 28.31% in 2021 and then skyrocketed 58.83% in 2025.
  • Tracing BMRN's Cash & Current Investments over 5 years: stood at $1.0 billion in 2021, then increased by 27.39% to $1.3 billion in 2022, then fell by 16.86% to $1.1 billion in 2023, then grew by 5.95% to $1.1 billion in 2024, then surged by 37.17% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Cash & Current Investments are $1.6 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025).